Two patients with insulin resistance due to decreased levels of insulin-receptor mRNA.
Mutations have been identified in the insulin-receptor gene in insulin-resistant patients. We studied two patients with acanthosis nigricans and insulin resistance caused by a decrease in the number of cell surface insulin receptors. Patient 1 was an 11-yr-old boy with a fasting insulin level of 2130 pM; patient 2 was a 14-yr-old girl with hyperandrogenism and a fasting insulin level of 580-740 pM. Based on Southern-blotting studies, the structure of both alleles of the insulin-receptor gene in both patients appeared to be grossly normal. There was no evidence of insertions, deletions, or major rearrangements. Moreover, the nucleotide sequences of all 22 exons of the gene were normal in both patients. Thus, the predicted amino acid sequences of both patients' insulin receptors were normal. In Epstein-Barr virus-transformed lymphoblasts from patient 1, insulin-receptor mRNA levels were so low they could not be detected with an RNase A protection assay, whereas mRNA levels from patient 2 were in the lower half of the normal range. By use of a more sensitive assay based on the polymerase chain reaction, insulin-receptor mRNA could be detected in Epstein-Barr virus-transformed lymphoblasts from both patients. Moreover, because of the existence of silent polymorphisms in the nucleotide sequences, it was possible to differentiate the two alleles of the insulin-receptor gene in both patients. In patient 2, the two alleles were expressed asymmetrically, with 90% of the mRNA molecules having been transcribed from one allele but only 10% transcribed from the second allele. This suggests that there is an unidentified mutation in the underexpressed allele that acts in a cis-dominant fashion to decrease insulin-receptor mRNA levels. However, in patient 1, both alleles were expressed symmetrically in similarly low levels. Although not proven, it seems likely that the mutations that decrease insulin-receptor mRNA levels in patient 1 also map to the insulin-receptor locus.
Imano
E
E
Diabetes Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892.
Kadowaki
H
H
Kadowaki
T
T
Iwama
N
N
Watarai
T
T
Kawamori
R
R
Kamada
T
T
Taylor
S I
SI
D000293:Adolescent; D001786:Blood Glucose / Q000378:metabolism; D015139:Blotting, Southern; D002096:C-Peptide / Q000097:blood; D002460:Cell Line; D002472:Cell Transformation, Viral; D002648:Child; D004247:DNA / Q000235:genetics / Q000302:isolation & purification; D015342:DNA Probes; D004262:DNA Restriction Enzymes; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology; D005260:Female; D004854:Herpesvirus 4, Human / Q000235:genetics; D006801:Humans; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D008214:Lymphocytes; D008297:Male; D012150:Polymorphism, Restriction Fragment Length; D012333:RNA, Messenger / Q000235:genetics* / Q000378:metabolism; D011972:Receptor, Insulin / Q000235:genetics* / Q000378:metabolism; D012016:Reference Values; D013739:Testosterone / Q000097:blood
D001786:Blood Glucose; D002096:C-Peptide; D015342:DNA Probes; D007328:Insulin; D012333:RNA, Messenger; D013739:Testosterone; D004247:DNA; D011972:Receptor, Insulin; D004262:DNA Restriction Enzymes